Joby Aviation closes $591 million stock offering with full underwriter option
Director John W. Kozarich of Ligand Pharmaceuticals Inc (NASDAQ:LGND) sold 467 shares of common stock on September 2, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales amounted to a total of $75774. The transaction comes as LGND trades near its 52-week high of $168.50, having delivered impressive returns of over 56% year-to-date. InvestingPro analysis indicates the stock is currently in overbought territory.
The shares were sold in three separate transactions, all at varying prices. The prices ranged from $161.5135 to $164.248.
Following the transactions, Kozarich directly owns 45522 shares of Ligand Pharmaceuticals .
The sales were executed under a pre-arranged trading plan adopted on March 7, 2025.
In other recent news, Ligand Pharmaceuticals has made several notable announcements. The company completed a $460 million convertible notes offering, with net proceeds amounting to approximately $445.1 million. This financial move included the full exercise of an option for additional notes, reflecting strong investor interest. In addition, Ligand’s second-quarter 2025 earnings report was robust, prompting Benchmark to raise its price target for the company to $175, maintaining a Buy rating. Oppenheimer also adjusted its price target for Ligand to $190, citing the mid-August capital raise as a significant factor. Furthermore, H.C. Wainwright increased its price target to $206, following an FDA update on the REMS labeling for FILSPARI, which included reduced liver function monitoring. These developments highlight a period of strategic financial maneuvers and regulatory advancements for Ligand Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.